What were the key takeaways from NRx Pharmaceuticals’s earnings call?

What is NRx Pharmaceuticals's latest dividend and current dividend yield?

What factors drove the changes in NRx Pharmaceuticals's revenue and profit?

What is the market's earnings forecast for NRx Pharmaceuticals next quarter?

What were the key takeaways from NRx Pharmaceuticals's earnings call?

What is NRx Pharmaceuticals's gross profit margin?

What is the revenue and EPS growth rate for NRx Pharmaceuticals year over year?

What does NRx Pharmaceuticals do and what are its main business segments?

- **Operational Turnaround**: FY2025 loss reduced by 12% to $16.2M; $7.8M cash on hand supports 2026 operations.
- **Pipeline Momentum**: KETAFREE (Q3 2026 approval), NRX-100 (broader depression indication), NRX-101 (DCS-TMS combo) target $750M+ ketamine market and $1B+ neuroplasticity opportunity.
- **Clinical Network Growth**: HOPE Therapeutics expanding to 10+ clinics by year-end, with EBITDA-positive revenue.
- **Strategic Differentiation**: Preservative-free ketamine and DCS-TMS integration position NRx for premium pricing and faster adoption.

**【CEO Opening Remarks】**
- **Pivotal Year Progress**: 2025 saw reduced operating expenses (-12%), ending with $7.8M cash, and a focus on three key drug approvals (KETAFREE, NRX-100, NRX-101). HOPE Therapeutics' clinics achieved EBITDA-positive growth, with plans to expand to 10+ locations by end-2026.
- **KETAFREE Update**: ANDA submitted in Q3 2025, with 3 registration batches manufactured. FDA preliminary bioequivalence determination received; awaiting final approval Q3 2026. Citizen petition to remove toxic preservative (benzethonium chloride) from all ketamine products under review.
- **NRX-100 Expansion**: FDA Type C meeting supports NDA filing using real-world evidence (65,000+ patients) for broader indication (12M+ patients with suicidal ideation). Targeting full approval by end-2027. Partnership with Osmind for data integration.
- **NRX-101 Innovation**: Sustained-release D-cycloserine (DCS) to enhance TMS efficacy. Expanded access program launched; Phase III trial planned for summer 2026. Market potential exceeds $1B for DCS-TMS combination therapy.
- **Strategic Partnerships**: Neurocare AG collaboration to integrate TMS devices with NRX-101, mirroring successful renal dialysis models. VA and military contracts for clinical services.

**【CFO Financial Commentary】**
- **Financial Health**: FY2025 loss from operations reduced to $16.2M (vs. $18.5M prior), driven by 41% R&D expense decline to $3.8M. G&A expenses stable at $13.1M. Cash reserves ($7.8M) sufficient for operations through 2026, supported by ATM activities and clinic revenue growth.
- **Liquidity Outlook**: Anticipated cash resources, combined with clinic revenue expansion and cost management, position the company for potential profitability by end-2026 if one pipeline success materializes.

**【Q&A Highlights】**
- **KETAFREE Commercialization**: Inventory strategy includes 200K+ units pre-approved; pricing strategy leverages preservative-free differentiation. FDA inspection and stability data review remain final hurdles.
- **NRX-100 Market Potential**: Broader label (12M+ patients) aligns with payer coverage thresholds (<$10K/year). SPRAVATO ($2B market) serves as benchmark for ketamine-based therapies.
- **DCS Extended Release**: In vitro testing underway to confirm steady-state efficacy for TMS augmentation. Dr. Joshua Brown's NIH/DARPA research supports clinical validation.
- **FDA Engagement**: Agency openness to real-world evidence and expanded indications underscores NRX-100's regulatory pathway confidence.


NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript

- **Revenue Breakthrough**: First-quarter $240K revenue from 22 days of clinic operations, up from $0 prior. 
- **Pipeline Milestones**: 
  - NRX-100 NDA submission complete; ONE-D protocol achieves 87% depression remission rate. 
  - NRX-101 Phase 3 trial planned for Q1 2026, with 1M doses manufactured. 
- **Strategic Scale**: 
  - $10.3M cash on hand; >$20M annualized revenue potential from clinic acquisitions. 
  - 50-person salesforce planned for NRX-101 launch in 2026. 
- **Market Impact**: 
  - 13M Americans with suicidal ideation annually; NRX-100 targets $750M ketamine market. 
  - ONE-D protocol deploys in Florida with portable TMS devices. 


**【Management Opening Remarks】**
- **Revenue Generation**: First-time quarterly revenue of $240,000 from 22 days of operations at HOPE Therapeutics' Florida clinics, driven by ketamine and TMS treatments. 
- **Pipeline Momentum**: 
  - NRX-100 (preservative-free IV ketamine) NDA submission nearing completion for suicidal depression. 
  - NRX-101 (DCS + lurasidone) Phase 3 trial planned for Q1 2026, with 1 million doses manufactured. 
  - ONE-D protocol combining TMS and DCS achieved 87% response rate in real-world data. 
- **Strategic Positioning**: $10.3M cash balance as of Q3, with $7.1M in cash equivalents. Expanded access programs for NRX-101 and ONE-D protocol launched. 

**【CFO Financial Commentary】**
- **Financial Performance**: 
  - Loss from operations: $4M (vs. $3M YoY), driven by R&D ($800K) and G&A expenses ($400K). 
  - Revenue growth potential: >$20M annualized from pipeline clinic acquisitions. 
- **Liquidity**: $10.3M cash post-October subscription receipts, supporting operations through Q2 2026. 
- **Key Metrics**: 
  - 60,000+ patient encounters for NRX-100, 1,000+ trial participants for NRX-101. 
  - 72% remission rate in ONE-D protocol for severe depression. 

**【Q&A Highlights】**
- **Regulatory & Commercial Strategy**: 
  - NRX-100: Seeking accelerated approval for suicidal depression, with FDA CNPV review expected. 
  - NRX-101: 50-person salesforce planned for bipolar depression indication. 
  - ONE-D protocol: First U.S. deployment in Florida, with portable TMS devices enabling broader reach. 
- **Manufacturing & Supply Chain**: 
  - Blow-Fill-Seal packaging for NRX-100 enables 1M+ monthly production capacity. 
  - Expanded access program for NRX-101 provides free doses to 25,000+ patients. 
- **Market Impact**: 
  - 13M Americans with suicidal ideation annually; CDC estimates 1 suicide every 11 minutes. 
  - Ketamine market projected at $750M, with NRX-100 targeting toxic-free alternative. 


NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript

- **Operational Efficiency**: 50% YoY reduction in quarterly operating loss, supported by $6.5M funding from long-term investors.
- **NRX-100 Regulatory Momentum**: Dual FDA pathways for preservative-free ketamine, with potential $750M market capture if BZT removed.
- **Breakthrough Therapy for Bipolar Depression**: NRX-101 module 3 filed, targeting 7M patients with unmet need for akathisia treatment.
- **Commercial Readiness**: Focused 20-person launch team planned for 2026, aligning with CNPV-accelerated approvals.
- **Balance Sheet Strength**: $2.9M cash post-Q2, no dilutive financing, positioning for 2026 milestones.

**【CEO Summary Section】**
- **Significant Operational Progress**: Reduced quarterly operating loss by 50% YoY, filed 80,000+ pages of regulatory data, and strengthened balance sheet with $6.5M funding from long-term investors.
- **NRX-100 Regulatory Milestones**: 
  - **Citizen Petition**: Seeking removal of toxic preservative BZT from ketamine, with FDA response expected within 6 months.
  - **Dual Approval Paths**: NDA for suicidal depression (Fast Track expanded to 13M patients) and ANDA for generic ketamine ($750M market). FDA identified minor manufacturing issue, resolution underway.
- **NRX-101 Breakthrough Therapy**: Filed module 3 for oral treatment of bipolar depression with akathisia, targeting 7M patients. Seeking accelerated approval for unmet need, with confirmatory RCT planned.
- **Hope Therapeutics Expansion**: Acquired Dura Medical approval, nearing clinic network closure. Aims to build national network of neuroplasticity-focused clinics, similar to DaVita dialysis model.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: Net loss $17.5M (vs. $7.9M YoY), driven by $12M non-cash fair value charges. Operating loss improved 47% to $3.7M, reflecting cost control.
- **Cash Position**: $2.9M as of June 30, with $6.5M raised post-quarter via registered direct offering. Sufficient funds to support operations into 2026.
- **Balance Sheet Health**: Reduced convertible debt, no warrants or dilutive features in new funding, enhancing investor alignment.

**【Q&A Highlights】**
- **Accelerated Approval Rationale**: NRX-101 targets akathisia/suicidality in bipolar depression, with real-world data showing 180,000+ patients treated. FDA may prioritize under CNPV for public health crisis.
- **Commercial Strategy**: Focused launch with ~20 reps/MSLs for NRX-100 (clinics/hospitals) and NRX-101 (1,500 bipolar psychiatrists), aiming for efficient profitability.
- **CNPV Clarification**: Voucher not for sale; FDA's 1-2 month review could accelerate NRX-100 approval, with onshore manufacturing commitment.

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

- **Breakthrough Regulatory Progress**: Initiated NDA for NRX-100 with 4x clinical trial validation vs. ECT. Filed patent for preservative-free ketamine with potential 2045 exclusivity. ANDA for toxic-free formulation under FDA priority review.
- **Game-Changing Pipeline**: NRX-101 Phase IIb/III trial shows 90% remission rates in bipolar depression with akathisia. NDA filing for accelerated approval this quarter targets $2B+ market.
- **Scaling Clinics at Scale**: Acquired 3 high-margin clinics ($15M+ annual runrate). Secured $10.3M non-dilutive financing. 20+ clinic roll-up strategy on track for 2025 profitability.
- **Cash Position Solid**: $5.5M cash + $10.3M committed financing. 37% expense reduction driving Q1 operating loss down 37% YoY. Projected end-2025 profitability.

**【CEO Summary Section】**
- **Regulatory Progress**: Initiated NDA for NRX-100 (preservative-free IV ketamine) with 4 clinical trials showing efficacy vs. placebo and ECT. Filed patent for preservative-free formulation, potentially extending exclusivity to 2045. ANDA for preservative-free ketamine under review due to FDA focus on removing toxic preservatives.
- **Pipeline Expansion**: NRX-101 (D-cycloserine + lurasidone) Phase IIb/III trial shows reduction in suicidality and akathisia vs. standard antidepressants. NDA filing for accelerated approval anticipated Q2 2025.
- **Hope Therapeutics Network**: Acquired 3 clinics (Kadima, Endura, Neurospa) with $15M+ annual revenue potential. Signed $10.3M term sheets for non-dilutive financing. Targeting 20+ clinics by end-2025 with 30%+ EBITDA margins.
- **Financial Health**: Reduced operating expenses by 37% YoY to $3.7M. Cash balance of $5.5M as of Q1, sufficient for operations through 2025. Projected profitability by end-2025 via clinic revenue and drug sales.

**【CFO Financial Review】**
- **Q1 2025 Results**: Net loss of $5.5M (vs. $6.5M YoY). R&D/G&A expenses down 53% to $3.7M. Operating loss of $3.8M (vs. $6.0M YoY). Cash runway extended through 2025 with $5.5M on hand and $10.3M in committed financing.
- **Cost Efficiency**: Achieved 37% expense reduction through operational restructuring. Anticipate continued margin improvement as clinic network scales.

**【Q&A Highlights】**
- **Patent Strength**: Preservative-free NRX-100 patent claims supported by toxicology data on benzalkonium chloride. Potential 20+ years of exclusivity if granted. pH-neutral subcutaneous formulation in bioequivalence trials.
- **International Expansion**: Active discussions with European partners for NRX-100 commercialization. Hope Therapeutics targeting US market first, with international roll-out potential post-spinout.
- **Regulatory Momentum**: FDA PDUFA dates expected Q4 2025 for NRX-100 and NRX-101. ANDA filing for preservative-free ketamine could accelerate market access beyond NDA approval.

NRx Pharmaceuticals (NRXP)-15 May 25-2025 Q1 Earnings call transcript

- **$300M+ Ketamine Deal**: Nonbinding term sheet for NRX-100 with milestone payments and royalties, validating preservative-free formulation.
- **2025 Profitability Target**: Hope Therapeutics clinics expected to generate $100M+ revenue, driving NRx to profitability.
- **Innovative Combination Therapy**: NRX-101 reduces suicidality and akathisia, addressing unmet need in bipolar depression.
- **Manufacturing Scale**: 1M+ doses/month capacity positions NRX-100 for $1B+ market opportunity.
- **Financial Strength**: $9.8M cash runway through 2025; no dilution from Hope Therapeutics expansion.

**【CEO Strategic Overview】**
- Transitioned from R&D-focused to revenue-generating healthcare company, targeting profitability by end of 2025.
- **NRX-100 Ketamine NDA Progress**: Initiated filing for suicidality indication; preservative-free formulation achieves 2+ years shelf stability. Secured nonbinding term sheet with commercial partner valued at >$300M in milestones + double-digit royalty.
- **NRX-101 Combination Therapy**: Accelerated NDA filing planned for Q2 2025 targeting bipolar depression with suicidal ideation. Demonstrated efficacy in reducing suicidality and akathisia, a novel safety profile.
- **Hope Therapeutics Expansion**: Acquired 3 Florida clinics (EBITDA-positive, $5M+ annual revenue each) and in talks for 12+ more. Aims to build 20+ clinic network by year-end 2025. Clinics integrate ketamine, TMS, digital therapeutics for long-term remission.
- **Manufacturing Scale**: 1M+ doses/month capacity for NRX-100; pH-neutral subcutaneous formulation development underway.

**【CFO Financial Highlights】**
- 2024 Full Year Results: 
  - R&D Expense: $6.2M (down 53.6% YoY)
  - G&A Expense: $13.5M (down 4.9% YoY)
  - Total Loss from Operations: $18.5M (down 33.5% YoY)
- Cash Position: $1.4M as of Dec 31, 2024 + $8.5M raised in Q1 2025. Sufficient for operations through 2025.
- **Hope Therapeutics Funding**: Clinics to be financed via bank loans (50% LTV), equity (20-30%), and NRx equity (remainder). No dilution to NRx shareholders.

**【Q&A Key Takeaways】**
- **Ketamine Preservative-Free Innovation**: Removed toxic benzethonium chloride, enabling single-use vials with 2+ years stability. ANDA filed for generic ketamine without preservative, creating >$1B market opportunity.
- **Acquisition Strategy**: Florida focus due to high-quality, integrated clinics. 50% bank financing, 20-30% equity, 30% NRx equity. 2025 target: 20+ clinics generating $100M+ revenue.
- **International Expansion**: France collaboration for European filings; Asian partnerships in development.
- **Shareholder Value**: Hope Therapeutics profits will roll up to NRx. Spinout of Hope shares to NRx holders planned post-FDA approvals.


Actual			-2.1	-1.1	-1.4	-1.5	-1.6	-1.2	-0.7	-0.5	-0.74	-0.75	-0.15	-0.7243	-0.34	-0.98	-0.27	-0.08
Forecast				-1	-1.4	-1.45	-1.35	-1.3333	-1.1	-0.7	-0.55	-0.695	-0.555	-0.3667	-0.2833	-0.1502	-0.1312	-0.07
Surprise	0.00%	0.00%	0.00%	-10.00%	0.00%	-3.45%	-18.52%	+10.00%	+36.36%	+28.57%	-34.55%	-7.91%	+72.97%	-97.52%	-20.01%	-552.46%	-105.79%	-14.29%

Actual	--	--	--	0	0	0	0	0	0	0	0	0	0	0	2.27M	0	242.00K	1.91M
Forecast	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	3.50M	6.01M	3.65M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-95.97%	-47.75%

NRXP

NRXP fundamentals

NRXP Q4 2025 Earnings

Earnings Call

You can ask Aime

NRXP

NRXP fundamentals

NRXP Q4 2025 Earnings

Earnings Call

NRXP Earnings Call Summary for Q4/20258:00 AM on Mar 24, 2026

NRXP Earnings Call Summary for Q3/20258:30 AM on Nov 17, 2025

NRXP Earnings Call Summary for Q2/20258:00 AM on Aug 20, 2025

NRXP Earnings Call Summary for Q1/20254:30 PM on May 15, 2025

NRXP Earnings Call Summary for Q4/2024Invalid Date on Mar 17, 2025

You can ask Aime